CEFTEZOLE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H12N8O4S3
Molecular Weight	440.481
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=C(CSC2=NN=CS2)CS[C@@H]3[C@H](NC(=O)CN4C=NN=N4)C(=O)N13

InChI

InChIKey=DZMVCVMFETWNIU-LDYMZIIASA-N

InChI=1S/C13H12N8O4S3/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25)/t8-,11-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C13H12N8O4S3
Molecular Weight	440.481
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17671744
Curator's Comment: Description is created based on several sources, including http://aksci.com/item_detail.php?cat=H709 and http://www.ncbi.nlm.nih.gov/pubmed/994325

Ceftezole sodium is a cephalosporin antibiotic. Ceftezole was found to be a broad-spectrum antibiotic, active in vitro against many species of gram-positive and gram-negative bacteria except Pseudomonas aeruginosa, Serratia marcescens and Proteus vulgaris. Ceftezole sodium is used as an injectable or through an intravenous mode of delivery. The bactericidal activity of ceftezole results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). The PBPs are transpeptidases which are vital in peptidoglycan biosynthesis. Therefore, their inhibition prevents this vital cell wall component from being properly synthesized. Ceftezole has been shown to exhibit potent alpha-glucosidase inhibitory activity. In in vitro alpha-glucosidase assays, ceftezole was shown to be a reversible, non-competitive inhibitor of yeast alpha-glucosidase with a Ki value of 5.78 x 10(-7) M when the enzyme mixture was pretreated with ceftezole. Ceftezole is used for the treatment of susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, endocarditis. Surgical prophylaxis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Alpha-glucosidase MAL12 2 Target ID: CHEMBL2932 Sources: http://www.ncbi.nlm.nih.gov/pubmed/17671744	Inhibitor 8504	2.1 µM [IC50]
Peptidoglycan biosynthesis 20 Target ID: map00550 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D01517	Inhibitor 8504
E. coli growth 6 Target ID: E. coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/994325	Inhibitor 8504
Klebsiella spp. growth 2 Target ID: Klebsiella spp. growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/994325	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Bronchial pneumonia 2 Sources: http://www.hailingpharm.com/page171?_l=en&product_id=56 http://www.sczyzj.com/en/injection/201411/20.html	Curative	Approved 8583	Ceftezole sodium for injection Approved Use Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Cystitis 27 Sources: http://www.sczyzj.com/en/injection/201411/20.html	Curative	Approved 8583	Ceftezole sodium for injection Approved Use Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Peritonitis 22 Sources: http://www.sczyzj.com/en/injection/201411/20.html	Curative	Approved 8583	Ceftezole sodium for injection Approved Use Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Septicaemia 15 Sources: http://www.sczyzj.com/en/injection/201411/20.html	Curative	Approved 8583	Ceftezole sodium for injection Approved Use Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis

C_max

Value	Dose	Analyte	Population
73.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
100.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
135.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
146.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
22.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3802300/	1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
0.64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.389 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
10.73 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389424/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3802300/	1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFTEZOLE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 g single, intravenous Recommended Dose: 2 g Route: intravenous Route: single Dose: 2 g Sources: https://pubmed.ncbi.nlm.nih.gov/7389424/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7389424/	Sources: https://pubmed.ncbi.nlm.nih.gov/7389424/
4 g 3 times / day multiple, intramuscular Recommended Dose: 4 g, 3 times / day Route: intramuscular Route: multiple Dose: 4 g, 3 times / day Sources: https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic	Other AEs: Pseudomembranous colitis, Nephrotoxicity... Other AEs: Pseudomembranous colitis Nephrotoxicity Sources: https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic

AEs

AE	Significance	Dose	Population
Nephrotoxicity		4 g 3 times / day multiple, intramuscular Recommended Dose: 4 g, 3 times / day Route: intramuscular Route: multiple Dose: 4 g, 3 times / day Sources: https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic
Pseudomembranous colitis		4 g 3 times / day multiple, intramuscular Recommended Dose: 4 g, 3 times / day Route: intramuscular Route: multiple Dose: 4 g, 3 times / day Sources: https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic

PubMed

Title	Date	PubMed
Relapsing peritonitis caused by Bordetella bronchiseptica in continuous ambulatory peritoneal dialysis patient: a case report.	2009-01	19194556
Exploring Mn-doped ZnS quantum dots for the room-temperature phosphorescence detection of enoxacin in biological fluids.	2008-05-15	18407673
Ceftezole, a cephem antibiotic, is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity.	2007-09	17671744
[Approach to the crystalline characteristics of ceftezole sodium].	2002-04	12579823

Patents

Sample Use Guides

In Vivo Use Guide

IM 2-4 g/day in 2-3 divided doses.

Route of Administration: Intramuscular

In Vitro Use Guide

Susceptibilities of 48 clinical isolates of S. aureus to ceftezole showed a peak at 0.20 ug/ml and no resistant strain with an MIC of 3.13 ug/ml or above was observed.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:31:51 GMT 2025` Edited by `admin` on `Mon Mar 31 18:31:51 GMT 2025`
Record UNII	2Z86SYP11W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

J01DB12

Preferred Name

English

CEFTEZOLE

Official Name

English

CEFTEZOLE [MI]

Common Name

English

Ceftezole [WHO-DD]

Common Name

English

(6R,7R)-8-OXO-7-(2-(1H-TETRAZOL-1-YL)ACETAMIDO)-3-((1,3,4-THIADIAZOL-2-YLTHIO)METHYL)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

ceftezole [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01DB12